Literature DB >> 22829399

Adjuvant thyroid remnant ablation in patients with differentiated thyroid carcinoma confined to the thyroid: a comparison of ablation success with different activities of radioiodine (I-131).

Marin Prpic1, Nina Dabelic, Josip Stanicic, Tomislav Jukic, Milan Milosevic, Zvonko Kusic.   

Abstract

OBJECTIVE: To assess efficiency of various I-131 activities on thyroid remnant ablation in thyroid cancer patients. The significance of patients' characteristics, pathologic features and levels of Tg were analyzed. PATIENTS AND METHODS: This study included 259 consecutive differentiated thyroid cancer patients, with disease confined to the thyroid, treated with I-131 after total thyroidectomy. Patients were divided into the three groups: 80 patients receiving low [1110-1850 MBq (30-50 mCi)], 121 intermediate [2775 MBq (75 mCi)] and 58 high [3700 MBq (100 mCi)] postoperative I-131 activities. Six to eight months after the application of radioiodine, measurements of TSH, Tg, anti-Tg antibodies (in hypothyroid state) together with ultrasound exam and whole-body scintigraphy were performed.
RESULTS: The ablation was significantly more effective (after the first application) in patients receiving 100 mCi of I-131-89.7% than in patients receiving lower activities (P = 0.016). There was no significant difference in ablation rate between the 30-50 mCi (77.5%) and 75 mCi (70.2%) groups. In the group receiving 30-50 mCi, patients with solitary tumors had significantly higher ablation rate (P = 0.038). In patients receiving 75 mCi ablation rates were higher among older patients (P = 0.005), with infiltration of the single lobe (P = 0.005), and with solitary tumor (P = 0.012). The rates of successful ablation after the second application of I-131 (after 12-16 months) amounted to 96, 97 and 96% in the 30-50, 75 and 100 mCi groups, respectively. The activity of I-131 and age were independent factors for thyroid ablation failure after the first application of I-131 (model of binary logistic regression).
CONCLUSION: The results of remnant ablation were satisfactory with all activities applied. Although after the first application of I-131 the activity of 100 mCi is significantly more effective in thyroid ablation than the administration of 30-50 mCi and 75 mCi, the ablation rates between all the three groups are similar (almost equal) after the second application. Thus, the activity to be administered may depend on patients' characteristics and a detailed consideration of the merits and demerits of each I-131 activity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22829399     DOI: 10.1007/s12149-012-0637-9

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  9 in total

1.  The outcome of I-131 ablation therapy for intermediate and high-risk differentiated thyroid cancer using a strict definition of successful ablation.

Authors:  Ken Watanabe; Mayuki Uchiyama; Kunihiko Fukuda
Journal:  Jpn J Radiol       Date:  2017-06-15       Impact factor: 2.374

Review 2.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

3.  Predictive factors of cytotoxic damage in radioactive iodine treatment of differentiated thyroid cancer patients.

Authors:  Satoru Monzen; Yasushi Mariya; Andrzej Wojcik; Chika Kawamura; Ayumi Nakamura; Mitsuru Chiba; Masahiro Hosoda; Yoshihiro Takai
Journal:  Mol Clin Oncol       Date:  2015-01-27

4.  Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma.

Authors:  Marin Prpic; Ivan Kruljac; Davor Kust; Lora S Kirigin; Tomislav Jukic; Nina Dabelic; Ante Bolanca; Zvonko Kusic
Journal:  Endocrine       Date:  2016-01-06       Impact factor: 3.633

Review 5.  Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer.

Authors:  Chae Moon Hong; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2018-05-02

6.  Clinical outcomes and associated factors of radioiodine-131 treatment in differentiated thyroid cancer with cervical lymph node metastasis.

Authors:  Chung-Jie Cao; Cheng-Yun Dou; Jiayan Lian; Zhao-Sheng Luan; Wen Zhou; Wenlin Xie; Li Chen; Kehua Zhou; Hong Lai
Journal:  Oncol Lett       Date:  2018-03-15       Impact factor: 2.967

7.  Can we safely reduce the administration of 131-iodine in patients with differentiated thyroid cancer? - experience of the Brugmann hospital in Brussels.

Authors:  Laura Iconaru; Felicia Baleanu; Georgiana Taujan; Ruth Duttmann; Linda Spinato; Rafik Karmali; Pierre Bergmann; Anne-Sophie Hambye
Journal:  Thyroid Res       Date:  2020-09-12

Review 8.  Assessment of Different Radioiodine Doses for Post-ablation Therapy of Thyroid Remnants: A Systematic Review.

Authors:  Mojtaba Ansari; Mostafa Rezaei Tavirani
Journal:  Iran J Pharm Res       Date:  2022-05-14       Impact factor: 1.962

9.  Silver Nanomaterial-Immobilized Desalination Systems for Efficient Removal of Radioactive Iodine Species in Water.

Authors:  Ha Eun Shim; Jung Eun Yang; Sun-Wook Jeong; Chang Heon Lee; Lee Song; Sajid Mushtaq; Dae Seong Choi; Yong Jun Choi; Jongho Jeon
Journal:  Nanomaterials (Basel)       Date:  2018-08-26       Impact factor: 5.076

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.